Non-vascular Stents Market

Non-vascular Stents Market was valued at US $ 1.79 Bn. in 2025. The global market is expected to grow at a CAGR of 4.8% during the forecast period. The market is expected to reach a value of US $2.49 Bn by 2032.

Non-vascular Stents Market Overview:

Non-vascular stents are used to unblock obstructions in non-vascular organs or bodily constructions such as the trachea and bronchi, the oesophagus, the biliary tree, the colon, and the urinary tract. Avascular stent is a petite method that is used to eliminate and preclude heart valve and artery obstructions. It is also engaged to give stenotic or blocked blood arteries internal structural provision.

To know about the Research Methodology:- Request Free Sample Report

It is the procedure of introducing a vascular stent into the body. Polyethene, polypropylene or non-absorbable materials like stainless steel or cobalt-chromium alloys are frequently used in vascular stents. They can range from cylindrical stent-grafts to inflatable metal tangles used during percutaneous vascular interferences to tubular stent grafts for aneurysm management.

Non-vascular Stents Market Dynamics:

Chronic Diseases are becoming more collective which is a major driving factor for the market:

The global occurrence of gastrointestinal disease is on the rise, which is anticipated to fuel the growth of the non-vascular stents market. Every year, over 24,000 Australians are detected with GI cancer, according to the GI Cancer Institute of Australia. In Addition, according to the American Cancer Society, nearly 26,560 which (16,160 in men and 10,400 in women) people in the United States were diagnosed with stomach cancer in 2021. Similarly by 2021, crudely 29,550 new occurrences of stomach cancer will have been identified.

Pulmonic stents are used to open tapering airways and ease the breathing process in conditions like chronic disruptive pulmonary disease, central airway obstruction, and asthma. According to the World Health Organization, more than 3Mn people die each year from chronic obstructive pulmonary disease (COPD), with 90% of these fatality rates befalling in low and middle-income countries like Azerbaijan, Belarus, Botswana, Albania, and Argentina. Kidney disease kills more individuals in the United States each year than prostate or breast cancer.

The high cost of Non-vascular Stents are a major restraining factor for the market:

An increase in the cost of several drugs of stents products and moderate use of dosages is a major factor that is hampering the growth of the market. Furthermore, total costs for those without health insurance range from $11,000 to $41,000 or more, conditional on the type of stent and extent of sojourn in the sanatorium. The National Pharmaceutical Pricing Authority (NPPA) has proclaimed that the expense of a drug-eluting stent would be fixed at $29,600, although the price of bare metal stents will be set at $7,260. In Addition, drug-eluting stents presently cost concerning 40,000 to 1.98 lakh rupees.

Lower Risk of Obstacle and help to avoid epidemic accumulation:

Stenting is a marginally aggressive substitute to coronary artery bypass grafting (CABG) surgery, similar to angioplasty. As a result, the risk of hitches is reduced than with CABG. Patients can commonly leave the hospital the next day, which is a far faster recovery than a CABG operation. Stenting drugs can also help to prevent various diseases such as, relieve chest pain, and promoting good blood flow to the heart, thus these factors give a huge opportunity for the Non-vascular market.

Government regulation and safety concerns among Stents products:

Stringent government rules in some emerging nations such as the United States, Canada and Mexico, as well as safety concerns, are expected to stalemate the development of the Non-Vascular Stents Market.

Non-vascular Stents Market Segment Analysis:

Non-vascular Stents Market Regional Insights:

The North American region held the largest market share, accounting for 32.78%, in 2025.This is due to the region's admirable healthcare system and the rising occurrence of lung cancer, glaucoma, central airway obstruction, COPD, asthma, and other chronic complaints. Accumulative industrial and material breakthroughs are supporting the expansion of specifically personalized stents for a convention in a variety of suggestions, which is driving the demand for non-vascular stents in a variety of solicitations. The use of stents in pulmonary, gastrointestinal, urological, and biliary censures is rising which is witnessing the growth of the non-vascular market in the U.S and Canada. In the United States, more than 1 Mn intestinal wall hernia conservations are accomplished each year, with inguinal hernia repairs accounting for 780,000 of these illustrations; males account for 92% of all inguinal hernia repairs.

However, the Asia Pacific region is expected to grow at a CAGR of 5.6% during the forecast period. Obligatory healthcare insurance requirements, as well as the increased incidence of gastrointestinal disorders and stomach cancer, are the main factors limiting market expansion in the Asia Pacific. The rising number of inhabitants and increase in apportionment for health care in various countries like India and China is a major reason for driving the growth of the Non-Vascular Stents market in the Asia Pacific region.

The objective of the report is to present a comprehensive analysis of the global market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants.

PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.

The reports also help in understanding the market dynamics, structure by analyzing the market segments and projecting the market size. Clear representation of competitive analysis of key players by Technology, price, financial position, product portfolio, growth strategies, and regional presence in the global market makes the report investor's guide.

Non-vascular Stents Market Recent Developments

In March 2024, Cook Medical and Getinge signed a commercial distribution contract for iCast covered stent system in the U.S. This agreement is expected to ensure that iCast covered stent system reaches the optimum number of patients who would benefit from the system in the U.S.

In March 2024, BD (Becton, Dickinson and Company), a worldwide medical technology corporation, announced the first patient enrollment in "AGILITY", an investigational device exemption (IDE) study. This study will evaluate the effectiveness and safety of the BD Vascular Covered Stent, for treating Peripheral Arterial Disease (PAD).

Non-vascular Stents Market Scope: Inquire before buying

Non-vascular Stents Market, by Region

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)

Key Player / Competitors Profile Covered in Global Non-vascular Stents Market Report in Strategic Perspective:

Given Imaging, Inc.
JINSHAN Science & Technology
Check-Cap
Koninklijke Philips N.V.
ACAMP
BDD Ltd
Cerner Corporation
FUJIFILM Holdings Corporation
Boston Scientific Corporation
PENTAX Medical
Medimetrics S.A. de C.V.
Medisafe
GE Healthcare
General Electric Company
Olympus Corporation
Medtronic
BD (Becton, Dickinson and Company)
ELLA-CS, s.r.o.
CONMED Corporation
HOBBS MEDICAL, INC
Cook Medical
TAEWOONG
Glaukos Corporation